Buy Revatio

Revatio

Revatio: Sildenafil 20 mg Pill - Overview

Revatio contains the active ingredient sildenafil and is supplied as a 20 mg oral tablet. Sildenafil belongs to the therapeutic class of phosphodiesterase-5 (PDE5) inhibitors and is widely recognised for its role in managing erectile dysfunction (ED). In the United Kingdom, Revatio is licensed for the treatment of pulmonary arterial hypertension (PAH). Because sildenafil is the same molecule used in other products that treat ED, Revatio is sometimes discussed in the context of erectile dysfunction, but it is not formally approved for that indication in the UK. Any use of Revatio for erectile dysfunction would be considered off-label and should only occur under direct supervision of a qualified healthcare professional.

How Sildenafil Works in the Body

Sildenafil inhibits the enzyme phosphodiesterase-5 (PDE5), which normally breaks down cyclic guanosine monophosphate (cGMP) in smooth muscle cells. By blocking PDE5, sildenafil increases cGMP levels, leading to:

• Relaxation of vascular smooth muscle in the corpus cavernosum of the penis (when sexual stimulation releases nitric oxide).
• Dilation of pulmonary arteries, reducing vascular resistance and improving exercise capacity in PAH.

The drug’s effect begins within 30-60 minutes after ingestion, peaks around 1-2 hours, and can last up to 12 hours, depending on the individual’s metabolism and dosage. Oral bioavailability of sildenafil tablets is roughly 40 %, and the medication is primarily metabolised by the liver enzyme CYP3A4 (with a lesser contribution from CYP2C9). The half-life is about 4 hours.

Approved Medical Uses of Revatio in the UK

• Pulmonary Arterial Hypertension (PAH): Revatio is indicated to improve exercise capacity and delay clinical worsening in adult patients with PAH. It is prescribed as part of a comprehensive PAH management plan, often together with other vasodilators or anticoagulants.
• Secondary Indications: The UK license does not include erectile dysfunction, but the same active ingredient (sildenafil) is approved for that purpose under different brand names (e.g., Viagra).

Off-Label and Investigational Applications

Off-Label Use for Erectile Dysfunction

Sildenafil’s efficacy for erectile dysfunction is well-documented in numerous randomised controlled trials. Although Revatio is not licensed for this purpose in the UK, clinicians may prescribe it off-label for ED when appropriate. Key points:

• Evidence Basis: The pharmacological action that benefits erectile function is identical across sildenafil products. Clinical guidelines for ED reference the dose range of 25-100 mg taken as needed; Revatio’s 20 mg strength is lower than the usual starting dose for ED but may be considered in patients who require a reduced dose due to tolerability or comorbidities.
• Regulatory Status: Off-label prescribing must be justified by clinical judgment, documented in the patient’s record, and accompanied by a risk-benefit discussion.
• Disclaimer: Off-label use requires individualized medical supervision and cannot replace an approved therapy without clear clinical justification.

Patient Suitability and Contraindications

Who Should Consider Revatio?

• Adults diagnosed with pulmonary arterial hypertension, irrespective of gender.
• Patients for whom a PDE5 inhibitor is appropriate based on haemodynamic assessment.

Absolute Contraindications

• Known hypersensitivity to sildenafil or any tablet excipients.
• Concurrent use of nitrates (e.g., nitroglycerin, isosorbide dinitrate) or nitric oxide donors-risk of severe hypotension.
• Severe uncontrolled hypertension (systolic >180 mmHg or diastolic >110 mmHg).

Relative Contraindications and Cautions

• Cardiovascular disease: Recent myocardial infarction, unstable angina, or severe heart failure require careful assessment.
• Renal impairment: Dose adjustment may be needed in patients with creatinine clearance <30 ml/min.
• Hepatic impairment: Patients with moderate to severe liver disease (Child-Pugh B or C) may need reduced dosing.
• Pregnancy & lactation: Sildenafil is classified as Category B3 in the UK; it is not recommended during pregnancy unless the benefit outweighs risk. It is excreted in breast milk; breastfeeding mothers should avoid use.
• Age extremes: Elderly patients may be more susceptible to hypotension and should start at the lowest effective dose.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Headache (often mild, transient)
• Flushing (warmth, redness of face)
• Indigestion or dyspepsia
• Nasal congestion
• Mild visual disturbances (tinting, increased brightness)

These effects typically resolve without intervention. If persistent, patients should inform their clinician.

Serious Adverse Events

• Sudden loss of vision (non-arteritic anterior ischemic optic neuropathy) - rare but requires immediate medical attention.
• Sudden hearing loss - rare, warrants urgent evaluation.
• Priapism (prolonged erection >4 hours) - medical emergency to prevent permanent tissue damage.
• Severe hypotension - especially when combined with nitrates or potent vasodilators.

Drug Interactions

• Nitrates (e.g., nitroglycerin) - contraindicated due to risk of marked hypotension.
• Alpha-blockers (e.g., doxazosin) - may cause additive blood pressure lowering; monitor closely.
• CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir) - increase sildenafil plasma concentrations; consider dose reduction.
• CYP3A4 inducers (e.g., carbamazepine, phenytoin) - may reduce efficacy; dosage adjustments may be needed.
• Other PDE5 inhibitors - concurrent use increases risk of adverse events; avoid.

Food and Lifestyle Interactions

• High-fat meals can delay absorption, slightly reducing peak concentration.
• Alcohol in moderate amounts generally does not alter efficacy but may exacerbate hypotension and dizziness.
• Driving or operating machinery: If experiencing dizziness or visual changes, patients should refrain until symptoms resolve.

Dosing and Administration Guidelines

• Standard adult dose for PAH: 20 mg Revatio taken three times daily, approximately 4-6 hours apart. This regimen reflects the licensed indication in the UK.
• Off-label dose for erectile dysfunction: Clinicians may prescribe a single 20 mg tablet taken as needed, about 30-60 minutes before anticipated sexual activity. Because the licensed dose for PAH is three times daily, using a single low dose for ED should be discussed explicitly with the prescriber.
• Renal or hepatic impairment: Start with 20 mg once daily; adjust based on clinical response and tolerability. Do not exceed the total daily dose recommended for the primary indication.
• Administration tips: Swallow the tablet whole with a glass of water. Do not crush or chew, as this may affect absorption.
• Missed dose: If a scheduled dose is forgotten, take it as soon as remembered unless it is within 2 hours of the next dose. Do not double the dose.
• Overdose: Symptoms may include severe hypotension, prolonged erection, or fainting. Seek urgent medical care; treatment is supportive (IV fluids, blood pressure monitoring). No specific antidote exists.
• Discontinuation: For PAH, abrupt cessation is not recommended; tapering is generally unnecessary but should be coordinated with the treating specialist. For ED, stop use if adverse effects become problematic.

Monitoring and Follow-Up

• Blood pressure and heart rate should be measured at baseline and periodically during therapy for PAH.
• Liver function tests may be considered in patients with known hepatic disease.
• Renal function assessment is advisable before initiation and during treatment in patients with impaired kidney function.
• Clinical response (e.g., six-minute walk distance for PAH, ability to achieve satisfactory erection for ED) should be evaluated after 4-8 weeks of therapy.
• Adverse event surveillance is essential; patients should report any visual or auditory changes promptly.

Storage and Handling

• Store Revatio tablets at room temperature (15-30 °C), protected from moisture and light.
• Keep the container tightly closed and out of reach of children.
• Do not use tablets after the expiry date printed on the packaging.
• If disposal is required, follow local NHS guidelines for medication waste (e.g., return to a pharmacy’s medicine take-back scheme).

Medication-Specific Glossary

Phosphodiesterase-5 (PDE5) inhibitor

A class of drugs that block the PDE5 enzyme, increasing cGMP levels and promoting smooth-muscle relaxation in blood vessels.

cGMP (Cyclic guanosine monophosphate)

A second messenger molecule that mediates vasodilation; elevated levels enhance blood flow to target tissues.

Pulmonary arterial hypertension (PAH)

A chronic condition characterised by high blood pressure in the arteries of the lungs, leading to reduced exercise capacity and right-heart strain.

Off-label use

Prescription of a medication for an indication, age group, dosage, or route of administration not officially approved by the regulatory authority.

Medical Disclaimer

This article provides educational information about Revatio (sildenafil 20 mg tablets) and is not a substitute for professional medical advice. Treatment decisions, including any off-label use for erectile dysfunction, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.